EssilorLuxottica : Below a resistance on the weekly chart
Entry price | Target | Stop-loss | Potential |
---|
€174.05 |
€158 |
€185 |
+9.22% |
---|
The EssilorLuxottica share has benefitted from renewed investor interest over the past months, which prompted it to return to important technical levels based on weekly price data. These are situated around 180.55 EUR. A phase during which profit-taking takes place appears to be the most likely scenario.
Summary● The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths● The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
● The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
● Over the last twelve months, the sales forecast has been frequently revised upwards.
● Sales forecast by analysts have been recently revised upwards.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses● With an expected P/E ratio at 31.73 and 28.99 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
● With an enterprise value anticipated at 3.49 times the sales for the current fiscal year, the company turns out to be overvalued.
● The company is highly valued given the cash flows generated by its activity.
● The company's earnings releases usually do not meet expectations.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.